JP2011526918A5 - - Google Patents

Download PDF

Info

Publication number
JP2011526918A5
JP2011526918A5 JP2011516833A JP2011516833A JP2011526918A5 JP 2011526918 A5 JP2011526918 A5 JP 2011526918A5 JP 2011516833 A JP2011516833 A JP 2011516833A JP 2011516833 A JP2011516833 A JP 2011516833A JP 2011526918 A5 JP2011526918 A5 JP 2011526918A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
release formulation
sustained release
oral sustained
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011516833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526918A (ja
JP6092514B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/049322 external-priority patent/WO2010002937A1/en
Publication of JP2011526918A publication Critical patent/JP2011526918A/ja
Publication of JP2011526918A5 publication Critical patent/JP2011526918A5/ja
Application granted granted Critical
Publication of JP6092514B2 publication Critical patent/JP6092514B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011516833A 2008-06-30 2009-06-30 ５−フルオロシトシン製剤およびその使用 Expired - Fee Related JP6092514B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7714208P 2008-06-30 2008-06-30
US61/077,142 2008-06-30
PCT/US2009/049322 WO2010002937A1 (en) 2008-06-30 2009-06-30 Formulations of 5-fluorocytosine and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014227208A Division JP6170896B2 (ja) 2008-06-30 2014-11-07 ５−フルオロシトシン製剤およびその使用

Publications (3)

Publication Number Publication Date
JP2011526918A JP2011526918A (ja) 2011-10-20
JP2011526918A5 true JP2011526918A5 (enExample) 2012-07-19
JP6092514B2 JP6092514B2 (ja) 2017-03-08

Family

ID=41466310

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011516833A Expired - Fee Related JP6092514B2 (ja) 2008-06-30 2009-06-30 ５−フルオロシトシン製剤およびその使用
JP2014227208A Expired - Fee Related JP6170896B2 (ja) 2008-06-30 2014-11-07 ５−フルオロシトシン製剤およびその使用
JP2017130096A Pending JP2017214398A (ja) 2008-06-30 2017-07-03 ５−フルオロシトシン製剤およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014227208A Expired - Fee Related JP6170896B2 (ja) 2008-06-30 2014-11-07 ５−フルオロシトシン製剤およびその使用
JP2017130096A Pending JP2017214398A (ja) 2008-06-30 2017-07-03 ５−フルオロシトシン製剤およびその使用

Country Status (11)

Country Link
US (4) US9320738B2 (enExample)
EP (1) EP2306823A4 (enExample)
JP (3) JP6092514B2 (enExample)
KR (2) KR101950635B1 (enExample)
CN (2) CN102076215A (enExample)
AU (1) AU2009267052B2 (enExample)
BR (1) BRPI0915284B1 (enExample)
CA (1) CA2724740C (enExample)
IL (3) IL209385A (enExample)
MX (2) MX337213B (enExample)
WO (1) WO2010002937A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69940521D1 (de) 1998-10-01 2009-04-16 Univ Southern California Retrovirales genübertragungssystem und entsprechendes verwendungverfahren
US9320738B2 (en) * 2008-06-30 2016-04-26 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
CN105624193B (zh) 2008-09-26 2021-07-13 索元生物医药(美国)有限公司 重组载体
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CA2764107A1 (en) 2009-06-17 2010-12-23 Tocagen Inc. Producer cells for replication competent retroviral vectors
WO2011057176A1 (en) * 2009-11-06 2011-05-12 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
US9669049B2 (en) 2010-10-31 2017-06-06 Tocagen Inc. Compositions comprising gamma retrovirus vectors and methods of treating proliferative disorders
EP2670368A4 (en) * 2011-02-03 2015-04-15 Pharmedica Ltd NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
WO2013004658A1 (en) * 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.
CN102579450B (zh) * 2012-02-10 2013-07-24 上海市嘉定区南翔医院 5-氟尿嘧啶在制备局限性慢性湿疹治疗药物上的应用
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
US11065311B2 (en) 2012-10-25 2021-07-20 Denovo Biopharma Llc Retroviral vector with mini-promoter cassette
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
MX2018002744A (es) 2015-09-04 2018-04-13 Tocagen Inc Vectores recombinantes que comprenden peptido 2a.
CA3056603A1 (en) * 2017-03-14 2018-09-20 Memorial Sloan Kettering Cancer Center Labeling, isolation, & analysis of rna from rare cell populations
US20190380965A1 (en) * 2018-06-15 2019-12-19 Hemant N. Joshi Quick Water-Dispersible Pharmaceutical Compositions of Flucytosine
EP3955943A4 (en) * 2019-02-22 2023-10-25 Candel Therapeutics, Inc. Gmci and ddri combination therapy for treating cancer
US11483244B2 (en) 2020-03-18 2022-10-25 Marvell Israel (M.I.S.L) Ltd. Packet buffer spill-over in network devices
CN111937887B (zh) * 2020-07-15 2021-09-07 南京师范大学 5-氟-2’-脱氧尿苷在抑制和/或防治螺旋藻规模化生产中褶皱臂尾轮虫的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2105486C (en) 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
FI980901A7 (fi) 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
DE69940521D1 (de) 1998-10-01 2009-04-16 Univ Southern California Retrovirales genübertragungssystem und entsprechendes verwendungverfahren
PL198797B1 (pl) * 1999-03-31 2008-07-31 Janssen Pharmaceutica Nv Zastosowanie wstępnie żelowanej skrobi
US6677155B1 (en) * 1999-04-22 2004-01-13 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
AU6085500A (en) 1999-07-08 2001-01-30 Regents Of The University Of California, The A lung cancer associated retrovirus, gene delivery vector and methods of use thereof
JP4021627B2 (ja) * 2000-03-22 2007-12-12 株式会社東芝 遺伝子検出用担体、及びインターフェロン療法の有効性を検出するためのその使用
AU2001268722B8 (en) 2000-06-23 2005-09-29 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
CN1244321C (zh) * 2003-06-26 2006-03-08 李勇 用于胃癌治疗的5－氟尿嘧啶胃内漂浮滞留双层缓释片
US20050049207A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
US8715727B2 (en) * 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
FR2874325B1 (fr) 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
WO2006127980A2 (en) 2005-05-25 2006-11-30 The Regents Of The University Of California Optimized core promoters and uses therefor
JPWO2007069358A1 (ja) * 2005-12-14 2009-05-21 キッセイ薬品工業株式会社 新規胃内滞留製剤
CN101085355B (zh) * 2007-06-20 2012-01-25 山东大学 5-氟胞嘧啶/类水滑石纳米杂化物及其制备方法
US20090068287A1 (en) 2007-09-12 2009-03-12 Susan Welsh Novel topical formulations of flucytosine and uses thereof
US9314524B2 (en) 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
US9320738B2 (en) * 2008-06-30 2016-04-26 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CN105624193B (zh) 2008-09-26 2021-07-13 索元生物医药(美国)有限公司 重组载体
CA2805937A1 (en) 2010-08-13 2012-02-16 Pioneer Hi-Bred International, Inc. Chimeric promoters and methods of use

Similar Documents

Publication Publication Date Title
JP6657454B2 (ja) ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス
ES2742525T3 (es) Composiciones de corticosteroides administradas oralmente
JP6170896B2 (ja) ５−フルオロシトシン製剤およびその使用
TWI302460B (en) Pharmaceutical compositions and use thereof
JP2016006108A5 (enExample)
US20230119239A1 (en) Oromucosal film compositions
CN101466392B (zh) 用于预防或治疗hiv感染的药用组合物及其应用
RU2015107517A (ru) Фармацевтические композиции мемантина
FI4138789T3 (fi) Uusi viivästetysti vapauttava koostumus annettavaksi suun kautta
WO2005055955B1 (en) DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY
CN111065384A (zh) 扑热息痛的口腔崩解膜组合物
CN114845700A (zh) Otf的可溶性背衬层
CN102357078A (zh) 一种缬沙坦固体分散体及其制备方法
CN104869983A (zh) 醋酸格拉替雷的透粘膜给药
TW200911303A (en) Powders for reconstitution
CN103550183A (zh) 一种盐酸曲美他嗪渗透泵控释片及其制备方法
JP5064226B2 (ja) 不眠症の治療において有用な新規な製剤処方
JP2010506855A5 (enExample)
WO2025120580A1 (en) Compositions and methods for initiating a mucosal immune response
WO2024220974A1 (en) Rimegepant fast-dissolving films for oral administration
TR201801650T1 (tr) Kontrollü salim propi̇veri̇n formülasyonlari
US20230364075A1 (en) Multiparticulate dosage forms comprising deutetrabenazine
JP2021523931A5 (enExample)
JP2012031164A (ja) フィルム状製剤
WO2007010930A1 (ja) 口腔内崩壊製剤用の薬物含有被覆微粒子及びその製造方法